Rosetta Genomics said this week that it has signed a deal making Warnex Medical Laboratories the exclusive distributor of Rosetta's three microRNA-based diagnostics in Canada.
Under the deal, Warnex will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.
The company will send tissue samples from its Canadian customers to Rosetta's Philadelphia-based lab for analysis.
Additional terms of the deal were not disclosed.
Rosetta has long been on the lookout for marketing partners for its miRNA tests. In April, it signed a deal giving Prometheus Laboratories the US rights to the three diagnostics (see RNAi News, 4/16/2009). In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).